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INTRODUCTION 
Work partially supported by Harvard Medical School-Portugal Program (HMSP-ICJ/0022/2011), FCT/Poly-Annual Funding Program and FEDER/Saúde XXI Program (Portugal).  
DIGE images were obtained in ITQB. This work was approved by the Ethical Committee of INSA.I.P.-Lisboa, Centro Hospitalar Lisboa-Norte., Faculdade de Ciências Médicas da Universidade Nova de Lisboa and Comissão 
Nacional de Proteção de Dados, Portugal. 
RESULTS I 
Catalase Validation  
 
      METHODS 
RESULTS II 
Peroxiredoxin Validation  
 
CONCLUSION 
The biochemical validation of 2DEbased proteomic results was performed by 
WesternBlot (WB) analysis or Enzymatic Assay for catalase (CAT) and 
peroxirdeoxin 2 (PRX-2) on nondepleted RBC cytoplasmic fractions prepared from 
blood samples collected from Snorer subjects (n=10)  and OSA (n=10) patients 
before and after underwent six month of CPAP treatment. Samples (n=50) were 
individually separated in duplicates on 4-12% SDS-PAGE mini gels. A non-reduced 
SDS-PAGE were used to analysed PRX-2. A Kinetic Enzymatic Assay was 
determined for CAT activity on these RBC lysates.  
A – 2DIGE showing 8 catalase (CAT) proteoforms identified in OSA and Snorer RBC samples collected at Evening or Morning 
time. The 6 most acidic CAT proteoforms (1‐6) were identified differentially abundant in OSA (Anova p≤ 0.05). The abundance 
level of the most prominent CAT proteoform (4) on the gel was significantly reduced (Anova, p≤ 0.01) in OSA Morning RBC 
compared with Snores  ones. 
B - Western blot and the respective histogram showing that there were no significant changes in the CAT relative abundance 
whatever patients/conditions were analyzed. 
C- Catalase Kinetic Activity (nmol Catalase/minute/mg of protein) were measured in RBC total cytosolic fraction of each 
patient/condition groups. The upper histogram representation shows that CAT activity was significantly lower (Anova p≤ 0.05) 
in OSA Morning RBC samples in comparison with both Snores Morning and OSA Evening samples. In contrast, CAT activity 
was significant higher (Anova p≤ 0.001) in OSA patients after underwent six month of CPAP treatment in comparison with 
both Snorers and non‐treated OSA patients. The lowest histogram representation shows that CAT activity was significantly 
lower (Anova, p≤ 0.05) in Morning RBC samples regardless of patient conditions.  
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A – 2DIGE showing two peroxiredoxin‐2 (PRX‐2) proteoforms indentified on OSA and Snorer RBC samples collected at 
Evening or Morning time. The acidic PRX 2 proteoform (1) was identified significantly higher abundant in OSA Morning 
samples compared with Snorer’s ones. No significant differences were observed among conditions for basic PRX‐2 
proteoform at 20 kDa (2).  
B and C - Western Blots (non-reduced SDS-PAGE) showing representative immunoblots for PRX‐2 and PRX‐O2/3 
(Hyperoxidized forms), respectively, identified in three OSA/Snores patients as example.  
HMW Dimeric (S‐S) forms (hyperoxidized) and LMW (‐S‐S‐) forms (Oxidized) of PRX 2 were highly increased in OSA RBC collected at 
Evening/Morning compared with Snorer’s ones. After CPAP treatment at least LMW (-S-S-) oxidized dimeric forms of PRX-2 were 
significantly reduced (Histogram B).  
By using a specific antibody for (SO2/3) hyperoxidized forms of PRX, we observed that both monomeric  and dimeric forms  of PRX2 
were highly hyperoxidized in OSA Morning samples compared with Snorer’s ones (Histogram C). CPAP treatment decreased 
significantly hyperoxidized monomeric and dimeric forms of PRX2. Multimeric hyperoxidized forms were observed almost exclusively 
after CPAP treatment, which may correspond to CPAP-induced chaperone activity  on PRX2.  
Our data indicate that in OSA RBC the activity and redox/oligomeric state events of CAT and PRX2, respectively showed dysregulated maybe in 
consequence of OSA-induced chronic oxidative stress.  
CPAP treatment was effective to partially recover OSA-induced CAT and PRX2  dysregulation by probably improving patient’s antioxidant 
capacity.  
We propose CAT and PRX2 as a promising biomarker for monitoring OSA severity and/or CPAP treatment effectiveness.   
AIMS 
Validate potential proteomic candidate biomarkers that we have identified in 
OSA RBC and may be associated with OSA  and OSA  associated  
cardiometabolic disorders. 
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Obstructive sleep apnea (OSA) is a sleep¬related breathing disorder 
characterized by recurrent episodes of apnea/and hypopnea during sleep with 
resultant  intermittent hypoxia and sleep fragmentation, leading to 
cardiometabolic diseases. OSA affects 3.7% to 26% of adult population, but 
frequently is underdiagnosed. By 2DIGE-proteomics approach, we have 
investigated red blood cells (RBC) in OSA to uncover new insights into putative 
chronic stress-induced RBC dysfunction that lead to inflammation and metabolic 
syndrome associated with OSA. A number of proteins as potential candidate 
biomarkers for OSA, such as the cytosolic antioxidant regulators, catalase (CAT) 
and peroxiredoxin2 (PRX2) was identified, needing additional biochemical 
research validation. 
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